Valvular heart disease in Parkinson's disease vs. controls: An echocardiographic study

Movement Disorders : Official Journal of the Movement Disorder Society
Cecilia PeraltaWerner Poewe

Abstract

Restrictive valvulopathy has been reported in association with dopamine agonist therapy in parkinsonian patients. The majority of reports have been related to pergolide, but anecdotal cases following treatment with bromocriptine or cabergoline have also been presented. It is presently unclear whether the potential induction of restrictive cardiac valvulopathy is a class effect of all dopamine agonists or if there is a differential risk between ergot and nonergot compounds. In this study, the frequency of a valvular regurgitation as assessed by routine transthoracic echocardiography was compared between 75 patients with Parkinson's disease (PD) treated with pergolide (n = 29), cabergoline (n = 13), pramipexole or ropinirole (n = 33), and 49 age-matched nonparkinsonian controls. The exposure to pergolide and cabergoline was associated with higher frequencies of valvular regurgitation grades 2 and 3 (31% and 47%) compared with age-matched controls (13%), while there was no increase of valvular regurgitation grades 2 and 3 in patients treated with nonergot compounds (10%). Evidence for restrictive valvulopathy was found in one patient treated with pergolide and cabergoline each. While this study shows similarly increased frequencie...Continue Reading

References

Oct 23, 2002·Cardiology in Review·Jacques SerratricePierre-Jean Weiller
Dec 14, 2002·Mayo Clinic Proceedings·Allison M PritchettRaul E Espinosa
Jul 2, 2003·Journal of the American Society of Echocardiography : Official Publication of the American Society of Echocardiography·William A ZoghbiUNKNOWN American Society of Echocardiography
Feb 24, 2004·Revue neurologique·V CalomneF Kempinere
Jun 16, 2004·Movement Disorders : Official Journal of the Movement Disorder Society·Olivier RascolJean-Louis Montastruc
Jun 16, 2004·Movement Disorders : Official Journal of the Movement Disorder Society·Judit HorvathAnthony E Lang
Oct 30, 2004·Movement Disorders : Official Journal of the Movement Disorder Society·Reinhard HorowskiHeinz H Pertz
Oct 30, 2004·Movement Disorders : Official Journal of the Movement Disorder Society·Olivier RascolJ-L Montastruc
Nov 4, 2005·The New England Journal of Medicine·Antonio PineroJose Fortes

❮ Previous
Next ❯

Citations

Sep 1, 2006·Journal of Neurology·Heinz ReichmannOlivier Rascol
Dec 17, 2008·Journal of Neural Transmission·Tomoko OedaHideyuki Sawada
Aug 21, 2007·Lancet Neurology·Angelo Antonini, Werner Poewe
Jan 5, 2007·The New England Journal of Medicine·René SchadeEdeltraut Garbe
Feb 28, 2008·Clinical Neuropharmacology·Gurutz Linazasoro, UNKNOWN Spanish Dopamine Agonists Study Group
Jun 2, 2007·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·A LledóP A Cavazzoni
Aug 22, 2008·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·J C MöllerW H Oertel
May 14, 2008·Annals of Family Medicine·William L BakerCraig I Coleman
Jun 26, 2008·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·Cindy ZadikoffPaula Rochon
Apr 18, 2008·Expert Review of Neurotherapeutics·Mitsutoshi Yamamoto, Anthony H V Schapira
Mar 8, 2008·Expert Opinion on Drug Safety·Ubaldo Bonuccelli, Roberto Ceravolo
Oct 29, 2015·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Miguel-Angel Maciá-MartínezAntoni F Z Wisniewski
Nov 19, 2008·Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia·Feriha OzerBeste Ozben
Mar 28, 2009·European Journal of Echocardiography : the Journal of the Working Group on Echocardiography of the European Society of Cardiology·Steven DroogmansGuy Van Camp
Sep 20, 2006·Clinical Therapeutics·Trond KvernmoErich Burger
Nov 10, 2006·Movement Disorders : Official Journal of the Movement Disorder Society·Susann JunghannsAlexander Storch
Jul 31, 2007·Movement Disorders : Official Journal of the Movement Disorder Society·Gregor SimonisRuth H Strasser
Oct 17, 2007·Nihon yakurigaku zasshi. Folia pharmacologica Japonica·Hiroyuki Arai, Junko Minami
Jan 11, 2012·Pharmacoepidemiology and Drug Safety·Ashok KrishnaswamiStephen K Vandeneeden
Jun 28, 2014·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Susan L Samson, Shereen Ezzat
Jun 15, 2011·Movement Disorders : Official Journal of the Movement Disorder Society·Vibeke Guldbrand RasmussenSteen Hvitfeldt Poulsen
Dec 30, 2011·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Gianluca TrifiròMiriam C Sturkenboom
Dec 24, 2015·Movement Disorders Clinical Practice·James A G CrispoDaniel Krewski
Nov 11, 2008·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Jessica K DevinLewis S Blevins
Jan 1, 2011·International Journal of Medicinal Chemistry·Shin Hisahara, Shun Shimohama
Sep 10, 2020·International Journal of Molecular Sciences·Shubhra AcharyaYvan Devaux
Nov 4, 2015·Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·N V Titova
Feb 20, 2021·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Florence van HunselAgnes Kant

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

© 2022 Meta ULC. All rights reserved